Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate hte Safety of Fentanyl TAIFUN Treatment after titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients on Maintenance Opioid Therapy
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active Comparator | Active Comparator | Current BTP Medication |
|
| Fentanyl TAIFUN | Experimental | Titration for dose confirmation followed by observation period |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fentanyl TAIFUN | Drug | Inhalation of Fentanyl via TAIFUN inhaler |
| |
| Measure | Description | Time Frame |
|---|---|---|
| AE Profile | 28 Days | |
| To characterize the safety of Fentanyl TAIFUN treatment vs. the current BTP treatment based on the AE profile | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| To estimate the proportion of patients taht can be titrated to an effective dose of Fentanyl TAIFUN | 28 Days | |
| To evaluate the efficacy of Fentanyl TAIFUN with the titrated dose and the current BTP treatment with the confirmed dose | 28 Days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Donna J Fordham | Contact | 941 742 6585 | fordhamd@akelapharma.com | |
| Ed E Margerrison, PhD | Contact | 512 517 9610 | margerrisone@akelapharma.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NZOZ | Recruiting | Włocławek | Wolnosc | 4487-800 | Poland |
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000701 | Analgesics, Opioid |
| D009020 | Morphine |
| D004091 | Hydromorphone |
| D010098 | Oxycodone |
| ID | Term |
|---|---|
| D009294 | Narcotics |
| D002492 | Central Nervous System Depressants |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Opioid |
| Drug |
Current optimized BTP treatment |
|
|
| To evaluate patients's preference between Fentanyl TAIFUN and the baseline BTP medication | 28 Days |
| To evaluate the sustained analgesic effect of Fentanyl TAIFUN and the current BTP treatment | 28 Days |
| D020164 | Chemical Actions and Uses |
| D000700 | Analgesics |
| D018689 | Sensory System Agents |
| D018373 | Peripheral Nervous System Agents |
| D002491 | Central Nervous System Agents |
| D045506 | Therapeutic Uses |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D003061 | Codeine |